Cipla to bring Covid-19 treatment remdesivir to SA
The manufacturer plans to sell the drug at around R5,600 for a five-day course
02 July 2020 - 19:46
Indian drug manufacturer Cipla is set to bring its generic version of Gilead Science’s coronavirus drug remdesivir to SA within the next few weeks, it emerged on Thursday.
Remdesivir is the first drug to have been approved by US authorities to treat Covid-19 and has been shown to speed up the recovery of hospitalised patients...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.